Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies

Eur J Nucl Med Mol Imaging. 2011 May:38 Suppl 1:S28-40. doi: 10.1007/s00259-011-1772-6. Epub 2011 Apr 12.


The technological advances in imaging and production of radiopharmaceuticals are driving an innovative way of evaluating the targets for antineoplastic therapies. Besides the use of imaging to better delineate the volume of external beam radiation therapy in oncology, modern imaging techniques are able to identify targets for highly specific medical therapies, using chemotherapeutic drugs and antiangiogenesis molecules. Moreover, radionuclide imaging is able to select targets for radionuclide therapy and to give the way to in vivo dose calculation to target tissues and to critical organs. This contribution reports the main studies published on matched pairs dosimetry with (124)I/(131)I- and (86)Y/(90)Y-labelled radiopharmaceuticals, with an emphasis on metaiodobenzylguanidine (MIBG) and monoclonal antibodies.

Publication types

  • Review

MeSH terms

  • 3-Iodobenzylguanidine / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Drug Therapy, Combination
  • Humans
  • Iodine Radioisotopes / administration & dosage
  • Neoplasms / radiotherapy
  • Positron-Emission Tomography / instrumentation*
  • Positron-Emission Tomography / methods
  • Radiation Dosage
  • Radioimmunotherapy / methods
  • Radiometry / methods*
  • Radiopharmaceuticals / administration & dosage
  • Radiotherapy Dosage
  • Tomography, Emission-Computed, Single-Photon / methods*
  • Yttrium Radioisotopes / administration & dosage


  • Antibodies, Monoclonal
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • 3-Iodobenzylguanidine